featured
Long-Term Safety of Patients With Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
Blood Adv 2022 Jun 10;6(8)14-15, U Jaeger, CS Tam, P Borchmann, JP McGuirk, M Johansen, EK Waller, SM Jaglowski, C Andreadis, RR Foley, JR Westin, I Fleury, PJ Ho, S Mielke, T Teshima, GA Salles, SJ Schuster, FC He, RT Maziarz, SA Mayer, S Makita, MJ Kersten, M Ghosh, ND Wagner-Johnston, K Kato, P Corradini, H Goto, S Colicino, A Agarwal, CL Lobetti-Bodoni, MR BishopFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.